ZA201006929B - Tetrazole compounds for reducing uric acid - Google Patents

Tetrazole compounds for reducing uric acid

Info

Publication number
ZA201006929B
ZA201006929B ZA2010/06929A ZA201006929A ZA201006929B ZA 201006929 B ZA201006929 B ZA 201006929B ZA 2010/06929 A ZA2010/06929 A ZA 2010/06929A ZA 201006929 A ZA201006929 A ZA 201006929A ZA 201006929 B ZA201006929 B ZA 201006929B
Authority
ZA
South Africa
Prior art keywords
uric acid
tetrazole compounds
reducing uric
reducing
tetrazole
Prior art date
Application number
ZA2010/06929A
Other languages
English (en)
Inventor
James Dennen O'neil
Ramachandran Arudchandran
Shalini Sharma
Original Assignee
Wellstat Immunotherapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Immunotherapeutics Llc filed Critical Wellstat Immunotherapeutics Llc
Publication of ZA201006929B publication Critical patent/ZA201006929B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2010/06929A 2008-04-30 2010-09-29 Tetrazole compounds for reducing uric acid ZA201006929B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4916708P 2008-04-30 2008-04-30
US9374308P 2008-09-03 2008-09-03
PCT/US2009/042298 WO2009134995A2 (en) 2008-04-30 2009-04-30 Tetrazole compounds for reducing uric acid

Publications (1)

Publication Number Publication Date
ZA201006929B true ZA201006929B (en) 2011-06-29

Family

ID=41255799

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/06929A ZA201006929B (en) 2008-04-30 2010-09-29 Tetrazole compounds for reducing uric acid

Country Status (15)

Country Link
US (2) US8410154B2 (cg-RX-API-DMAC7.html)
EP (1) EP2282736B1 (cg-RX-API-DMAC7.html)
JP (1) JP5431457B2 (cg-RX-API-DMAC7.html)
KR (1) KR101613611B1 (cg-RX-API-DMAC7.html)
CN (1) CN102014898B (cg-RX-API-DMAC7.html)
AU (1) AU2009243028B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0910541B8 (cg-RX-API-DMAC7.html)
CA (1) CA2722624C (cg-RX-API-DMAC7.html)
ES (1) ES2561039T3 (cg-RX-API-DMAC7.html)
IL (1) IL209004A (cg-RX-API-DMAC7.html)
MX (1) MX2010011603A (cg-RX-API-DMAC7.html)
NZ (1) NZ588374A (cg-RX-API-DMAC7.html)
RU (1) RU2522458C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009134995A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201006929B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0924547B1 (pt) 2008-03-13 2021-08-17 Wellstat Therapeutics Corporation Composto ácido 2-(3-(2,6-dimetilbenzilóxi)-4-metilfenil)acético, sua composição, bem como seu uso
AU2009243028B2 (en) 2008-04-30 2015-01-29 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid
CN102573462B (zh) * 2009-10-13 2014-04-16 维尔斯达医疗公司 用于降低尿酸的3位取代的化合物
US20130331452A1 (en) * 2010-09-08 2013-12-12 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
EP3501520A1 (en) * 2011-11-03 2019-06-26 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
CA2859693C (en) * 2011-11-04 2018-05-22 Cymabay Therapeutics, Inc. Methods for treating gout flares
MX2014008484A (es) * 2012-01-27 2014-10-14 Teijin Pharma Ltd Agente terapeutico para la diabetes mellitus.
TW201443025A (zh) * 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
CN104292176B (zh) * 2014-10-07 2016-06-29 张远强 一种含卤代苯的四氮唑乙酸类化合物、其制备方法和用途
CN104292177B (zh) * 2014-10-07 2016-08-17 张远强 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途
CN104262277B (zh) * 2014-10-07 2016-06-22 张远强 含硝基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途
JP6192142B2 (ja) * 2016-09-13 2017-09-06 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 痛風発赤の治療方法
RU2683570C1 (ru) * 2018-05-23 2019-03-29 Евгений Иванович Верещагин Композиция из растительных компонентов, обладающая способностью снижать уровень мочевой кислоты сыворотки крови
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN114805233A (zh) * 2022-03-30 2022-07-29 华南理工大学 苯基四氮唑类xor抑制剂及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021556A (en) * 1972-06-08 1977-05-03 Icn Pharmaceuticals, Inc. Xanthine oxidase inhibitors
US4024253A (en) 1973-04-20 1977-05-17 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Treatment of elevated histamine and uric acid levels
US4182764A (en) * 1973-10-11 1980-01-08 Merck & Co., Inc. Tetrazole derivatives of [1-oxo-2-aryl or thienyl-2-substituted-5-indanyloxy(or thio)]alkanoic acids
US4874777A (en) 1987-04-10 1989-10-17 Eli Lilly And Company Leukotriene antagonists
US4845231A (en) 1988-02-12 1989-07-04 American Home Products Corporation Tetrazoles and their use as hypoglycemic agents
FR2631827B1 (fr) 1988-05-27 1992-03-27 Delalande Sa Nouveaux derives d'(hetero)aryl-5 tetrazole, leur procede de preparation et leur application en therapeutique
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
US5591862A (en) 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
RU2144533C1 (ru) * 1994-12-09 2000-01-20 Такеда Кемикал Индастриз, Лтд. Производные тетразола, способ их получения и фармацевтические композиции на их основе
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
EA200000427A1 (ru) 1997-10-17 2001-02-26 Авентис Фармасьютикалз Продактс Инк. Терапевтические применения хинолиновых производных
EP1127882A1 (en) * 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
ES2441874T3 (es) * 2001-06-12 2014-02-06 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos
AU2003226094A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
JP2004197711A (ja) * 2002-12-20 2004-07-15 Honda Motor Co Ltd 回転流体機械
BRPI0408229A (pt) * 2003-03-11 2006-02-21 Novo Nordisk As preparação farmacêutica, métodos para preparar um ligando de ligação de zinco, para prolongar a ação de uma preparação de insulina estabilizada por ácido e para tratar diabete do tipo 1 ou tipo 2, e, uso de uma preparação
AR051780A1 (es) 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
BRPI0924547B1 (pt) 2008-03-13 2021-08-17 Wellstat Therapeutics Corporation Composto ácido 2-(3-(2,6-dimetilbenzilóxi)-4-metilfenil)acético, sua composição, bem como seu uso
AU2009243028B2 (en) 2008-04-30 2015-01-29 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid

Also Published As

Publication number Publication date
AU2009243028B2 (en) 2015-01-29
JP2011519865A (ja) 2011-07-14
CA2722624C (en) 2017-03-21
US8889724B2 (en) 2014-11-18
EP2282736A2 (en) 2011-02-16
KR20100135851A (ko) 2010-12-27
CN102014898B (zh) 2013-01-23
CN102014898A (zh) 2011-04-13
WO2009134995A3 (en) 2009-12-23
RU2010148762A (ru) 2012-06-10
EP2282736A4 (en) 2011-06-15
BRPI0910541B1 (pt) 2019-12-03
MX2010011603A (es) 2011-01-25
IL209004A0 (en) 2011-01-31
US8410154B2 (en) 2013-04-02
CA2722624A1 (en) 2009-11-05
WO2009134995A2 (en) 2009-11-05
HK1147446A1 (en) 2011-08-12
ES2561039T3 (es) 2016-02-24
JP5431457B2 (ja) 2014-03-05
NZ588374A (en) 2012-11-30
RU2522458C2 (ru) 2014-07-10
US20130336949A1 (en) 2013-12-19
EP2282736B1 (en) 2015-11-11
KR101613611B1 (ko) 2016-04-19
US20110206653A1 (en) 2011-08-25
BRPI0910541B8 (pt) 2021-05-25
AU2009243028A1 (en) 2009-11-05
IL209004A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
ZA201006929B (en) Tetrazole compounds for reducing uric acid
IL247136B (en) Compounds for reducing uric acid and their uses
PT2264009T (pt) Composto do ácido piridilaminoacético
HUS1700051I1 (hu) Pirrolopiridin vegyületek, mint CDK inhibitorok
ZA201008096B (en) Carboxylic acid compound
ZA201203615B (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
PL2178840T3 (pl) Pochodne kwasu azabifenyloaminobenzoesowego jako inhibitory dhodh
SI2192109T1 (sl) Biciklični aminokislinski derivati
GB0800035D0 (en) Compounds
EP2432774A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES
EP2315808A4 (en) POLYCARBONATE-ACIDICALLY MODIFIED POLYLACTIC ACID COMPOSITION RESISTANT TO SHOCK
IL210935A0 (en) Anti-malarial compounds
IL206524A0 (en) 4-dimethylminobutyric acid derivatives
GB0800367D0 (en) Compounds
PL2187863T3 (pl) Przeciwpotowe sole okso-heksameryczny cyrkon-oktaaminokwasu
EP2383275A4 (en) PROCESS FOR SYNTHESIZING O-DIPHENYLPHOSPHINOBENZOIC ACID
PT1849360E (pt) Novo uso para ácido 2-hidroxi-4-metiltiobutanóico (hmtb)
GB0801220D0 (en) Compounds
SG10201405790UA (en) Composition for lowering blood uric acid level
GB0821135D0 (en) Lanthanide compounds
GB0801265D0 (en) Compounds
HU0800250D0 (en) Otuction of glycosid compounds organist acid hydrolyris
ZA201000383B (en) Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
GB0820676D0 (en) Benzimidazole compounds
PL385746A1 (pl) Nowe związki hybrydowe porfiryna-furoksan